Lifeon Pharmaceutical released its performance for the first three quarters, with a net profit attributable to the parent company of 121 million yuan, a year-on-year increase of 1.65%

According to the Zhitong Finance APP, Lifeon Pharmaceutical released its third-quarter report for 2025. In the first three quarters, the company achieved operating revenue of 1.081 billion yuan, a year-on-year decrease of 3.95%. The net profit attributable to shareholders of the listed company was 121 million yuan, a year-on-year increase of 1.65%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 89.3546 million yuan, a year-on-year decrease of 20.23%

A-share innovative drug concept stocks fluctuated lower, with InventisBio falling over 10%. Other stocks such as Huahai Pharmaceutical, JENKEM, Lifeon Pharmaceutical, JOINN, Guangsheng Tang, HitGen, and Baillie Gifford also dropped more than 6%

Lifeon Pharmaceutical: Gao Meihua reduced her stake by 0.16%

Lifeon Pharmaceutical announced that Gao Meihua will reduce her holdings in the company by 300,000 shares through centralized bidding transactions from July 28, 2025, to August 29, 2025, accounting for 0.16% of the company's total share capital, with an average reduction price of 29.71 yuan/share, and a reduction price range of 27.44 yuan/share to 37 yuan/share; after the reduction, she holds 6.1447 million shares, accounting for 3.23%, and the reduction plan has been completed

Ophthalmology medical concept stocks surged, SPAS hit the daily limit in the afternoon

Ophthalmology medical concept stocks surged during the session, with SPAS hitting the daily limit, Xingqi Eye Medicine rising over 10%, Lifeon Pharmaceutical previously hitting the daily limit, and Bio-S, Eyebright Medical, GZYK, and HESH also following suit

Lifeon Pharmaceutical released its performance for the first half of the year, with a net profit attributable to the parent company of 90.2271 million yuan, an increase of 16.53%

According to the Zhitong Finance APP, Lifeon Pharmaceutical released its semi-annual report for 2025, with operating revenue of 732 million yuan, a year-on-year decrease of 4.80%. The net profit attributable to shareholders of the listed company was 90.2271 million yuan, a year-on-year increase of 16.53%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 66.2209 million yuan, a year-on-year decrease of 9.68%. The basic earnings per share were 0.47 yuan